Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.57 |
| ▸ | APP | P05067 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.45 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12766869 | 0.89 | MCHR1 (0.55) | MCHR1APPKMT2AHTTHDAC3 | |
| SCHEMBL12964611 | 0.84 | MCHR1 (0.51) | MCHR1KMT2AHTTHDAC3HDAC1 | |
| SCHEMBL1499645 | 0.83 | MCHR1 (0.62) | MCHR1KMT2A | |
| SCHEMBL12964827 | 0.82 | MT-CO2 (0.55) | APPKMT2AHTTRAD52 | |
| SCHEMBL12767204 | 0.79 | KMT2A (0.65) | MCHR1APPKMT2ARXFP1 | |
| SCHEMBL12760659 | 0.78 | MCHR1 (0.48) | MCHR1KMT2AHTTHDAC3HDAC1 | |
| SCHEMBL12760660 | 0.78 | MCHR1 (0.48) | MCHR1KMT2AHTTHDAC3HDAC1 | |
| SCHEMBL12964680 | 0.77 | MT-CO2 (0.58) | APPKMT2AHTTRAD52 | |
| SCHEMBL1499494 | 0.76 | PTGS2 (0.56) | APPKMT2ARAD52 | |
| SCHEMBL12966982 | 0.76 | ATG4B (0.43) | APPKMT2ARAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | ABIVAX (FR) | 2020-01-21 | — | — | US | disclosed |
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | ABIVAX (FR) | 2018-05-10 | — | — | US | disclosed |
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | ABIVAX (FR) | 2018-05-10 | — | — | US | disclosed |
| US-9890112-B2 | Compounds for use as therapeutic agents affecting p53 expression and/or activity | ABIVAX (FR) | 2018-02-13 | — | — | US | disclosed |
| US-9890112-B2 | Compounds for use as therapeutic agents affecting p53 expression and/or activity | ABIVAX (FR) | 2018-02-13 | — | — | US | disclosed |
| US-20140206690-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIETE SPLICOS (FR) | 2014-07-24 | — | — | US | disclosed |
| US-20140206690-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIETE SPLICOS (FR) | 2014-07-24 | — | — | US | disclosed |
| WO-2012131656-A2 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIÉTÉ SPLICOS (FR) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | TP53, TP53BP1, BCOR | MCHR1 2785/4885APP 3437/4885KMT2A 3766/4885 |
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | TP53, TP53BP1, BCOR | MCHR1 2785/4885APP 3437/4885KMT2A 3766/4885 |
| US-20140206690-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | TP53, CBR3, TP53BP1 | MCHR1 1928/4885APP 2435/4885KMT2A 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.